HUE058940T2 - Heterociklilamino-szubsztituált triazolok mint a RHO-asszociált protein kináz modulátorai - Google Patents

Heterociklilamino-szubsztituált triazolok mint a RHO-asszociált protein kináz modulátorai

Info

Publication number
HUE058940T2
HUE058940T2 HUE19702694A HUE19702694A HUE058940T2 HU E058940 T2 HUE058940 T2 HU E058940T2 HU E19702694 A HUE19702694 A HU E19702694A HU E19702694 A HUE19702694 A HU E19702694A HU E058940 T2 HUE058940 T2 HU E058940T2
Authority
HU
Hungary
Prior art keywords
heterocyclylamino
rho
modulators
protein kinase
associated protein
Prior art date
Application number
HUE19702694A
Other languages
English (en)
Inventor
Clifford Jones
Peter Bunyard
Gary Pitt
Liam Byrne
Thomas Pesnot
Nicolas Guisot
Original Assignee
Redx Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redx Pharma Plc filed Critical Redx Pharma Plc
Publication of HUE058940T2 publication Critical patent/HUE058940T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HUE19702694A 2018-01-25 2019-01-25 Heterociklilamino-szubsztituált triazolok mint a RHO-asszociált protein kináz modulátorai HUE058940T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1801226.0A GB201801226D0 (en) 2018-01-25 2018-01-25 Modulators of Rho-associated protein kinase

Publications (1)

Publication Number Publication Date
HUE058940T2 true HUE058940T2 (hu) 2022-09-28

Family

ID=61558335

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19702694A HUE058940T2 (hu) 2018-01-25 2019-01-25 Heterociklilamino-szubsztituált triazolok mint a RHO-asszociált protein kináz modulátorai

Country Status (25)

Country Link
US (2) US11497751B2 (hu)
EP (2) EP3743420B1 (hu)
JP (2) JP2021512158A (hu)
KR (1) KR20200113216A (hu)
CN (1) CN111655681B (hu)
AU (1) AU2019213214B2 (hu)
BR (1) BR112020013759A2 (hu)
CA (1) CA3088330A1 (hu)
CY (1) CY1125017T1 (hu)
DK (1) DK3743420T3 (hu)
EA (1) EA202091711A1 (hu)
ES (1) ES2907833T3 (hu)
GB (1) GB201801226D0 (hu)
HR (1) HRP20220269T8 (hu)
HU (1) HUE058940T2 (hu)
IL (1) IL275988B2 (hu)
LT (1) LT3743420T (hu)
MX (1) MX2020007898A (hu)
PH (1) PH12020550986A1 (hu)
PL (1) PL3743420T3 (hu)
PT (1) PT3743420T (hu)
SG (1) SG11202006087UA (hu)
SI (1) SI3743420T1 (hu)
WO (1) WO2019145729A1 (hu)
ZA (1) ZA202003983B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
CN111718310B (zh) * 2019-08-19 2021-06-11 中国药科大学 苯基取代的五元杂环类化合物及其制备方法、用途和药物组合物
CN110845410B (zh) * 2019-10-29 2021-02-26 暨明医药科技(苏州)有限公司 一种一锅法制备6,7-二甲氧基-3,4-二氢异喹啉盐酸盐的方法
CA3226387A1 (en) * 2021-07-26 2023-02-02 Joel D. Moore Rock2 inhibitors and uses thereof
CN113999211B (zh) * 2021-11-23 2022-11-29 郑州大学 一类特异性抗前列腺癌活性的含1,2,3-三氮唑的吲唑骨架衍生物
GB202200735D0 (en) * 2022-01-20 2022-03-09 Redx Pharma Plc Compounds
WO2023182856A1 (ko) * 2022-03-24 2023-09-28 서울대학교산학협력단 로-키나제 억제제를 포함하는 켈로이드 등 피부 섬유화 질환의 예방 또는 치료용 약학적 조성물 및 그의 용도
CN116891460A (zh) * 2023-07-12 2023-10-17 浙江大学 一种吲唑类衍生物或其药用盐及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207396D0 (en) 1992-04-03 1992-05-13 Merck Sharp & Dohme Therapeutic agents
CA2422367C (en) * 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CL2003002353A1 (es) * 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
WO2004052280A2 (en) * 2002-12-10 2004-06-24 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
JP2007530589A (ja) * 2004-03-26 2007-11-01 アンフォラ ディスカバリー コーポレーション 特定のトリアゾールを基礎とする化合物、組成物、およびそれらの使用
WO2006135383A2 (en) 2004-08-04 2006-12-21 Myriad Genetics, Inc. Indazoles
WO2007139967A2 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102007022565A1 (de) * 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclische Indazolderivate
US8344144B2 (en) * 2008-06-18 2013-01-01 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
CN102884060B (zh) * 2010-03-24 2019-07-19 阿米泰克治疗方案公司 用于抑制激酶的杂环化合物
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
US9073892B2 (en) * 2010-12-20 2015-07-07 Merck Serono S.A. Indazolyl triazol derivatives
KR20140131955A (ko) * 2012-03-09 2014-11-14 카나 바이오사이언스 인코포레이션 신규 트리아진 유도체
EP3262041A4 (en) * 2015-02-27 2018-08-01 Lycera Corporation Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
UA127863C2 (uk) 2015-12-16 2024-01-31 Локсо Онколоджі, Інк. Сполуки, які можна застосовувати як інгібітори кінази
KR102469161B1 (ko) * 2017-06-30 2022-11-23 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Rho-관련 단백질 키나아제 억제제, Rho-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase

Also Published As

Publication number Publication date
CN111655681A (zh) 2020-09-11
CN111655681B (zh) 2024-01-05
US20230021916A1 (en) 2023-01-26
WO2019145729A9 (en) 2020-07-30
EA202091711A1 (ru) 2020-10-20
US20210038606A1 (en) 2021-02-11
CA3088330A1 (en) 2019-08-01
HRP20220269T1 (hr) 2022-05-13
AU2019213214A1 (en) 2020-07-09
US11878020B2 (en) 2024-01-23
DK3743420T3 (da) 2022-03-07
JP2021512158A (ja) 2021-05-13
IL275988B2 (en) 2023-07-01
PL3743420T3 (pl) 2022-03-21
EP4026834A1 (en) 2022-07-13
SI3743420T1 (sl) 2022-06-30
ES2907833T3 (es) 2022-04-26
PH12020550986A1 (en) 2021-03-22
GB201801226D0 (en) 2018-03-14
IL275988A (en) 2020-08-31
US11497751B2 (en) 2022-11-15
WO2019145729A1 (en) 2019-08-01
KR20200113216A (ko) 2020-10-06
HRP20220269T8 (hr) 2022-12-09
JP2024026193A (ja) 2024-02-28
MX2020007898A (es) 2020-09-07
ZA202003983B (en) 2023-07-26
EP3743420B1 (en) 2021-12-15
SG11202006087UA (en) 2020-08-28
LT3743420T (lt) 2022-02-25
EP3743420A1 (en) 2020-12-02
CY1125017T1 (el) 2023-03-24
BR112020013759A2 (pt) 2020-12-01
AU2019213214B2 (en) 2023-06-29
IL275988B1 (en) 2023-03-01
PT3743420T (pt) 2022-02-04

Similar Documents

Publication Publication Date Title
IL275988A (en) Heterocyclamino-converted triazoles as modulators of rho-related protein kinase
IL287136B1 (en) Receptor inhibitors - interacting with protein kinase 1
ZA201805879B (en) Inhibitors of wdr5 protein-protein binding
EP3177295A4 (en) Uses of salt-inducible kinase (sik) inhibitors
EP3247692A4 (en) INHIBITORS OF TRKA KINASE
EP3423437A4 (en) INHIBITORS OF THE LINK BETWEEN THE WDR5 PROTEIN AND ITS LIAISON PARTNERS
EP3668839A4 (en) HETEROCYCLIC INHIBITORS OF THE ATR KINASE
EP3651768A4 (en) HETEROCYCLIC INHIBITORS OF THE ATR KINASE
EP3679031A4 (en) PROTEIN WDR5-PROTEIN INHIBITORS
IL304110A (en) Keap1–nrf2 protein–protein interaction inhibitors
EP3262041A4 (en) Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
EP3675861A4 (en) ALPHA SUPERWINDING PROTEIN KINASE INHIBITORS ("COILED-COIL") ASSOCIATED WITH RHO
EP3654970A4 (en) INHIBITORS OF RHO-ASSOCIATED DOUBLE-HELD PROTEINKINASE
ZA202000107B (en) Aminothiazole compounds as protein kinase inhibitors
IL283408A (en) Pyrazoles as modulators of hemoglobin
ZA201808238B (en) Certain protein kinase inhibitors
SG11202000621VA (en) Inhibitors of ror?
EP3134390A4 (en) Small molecule inhibitors of g protein coupled receptor 6 kinase polypeptides
EP3555092A4 (en) PROTEIN KINASE INHIBITORS
EP3134399A4 (en) Small molecule inhibitors of g protein coupled receptor 6 kinases polypeptides
EP3654972A4 (en) KINASE PROTEIN INHIBITORS CONTAINING A COIL COIL ASSOCIATED WITH RHO
LT3632912T (lt) Piridochinazolino dariniai, naudingi kaip proteinkinazės inhibitoriai
GB201700484D0 (en) Modulators of Rho-associated protein kinase
GB201700490D0 (en) Modulators of rho-associated protein kinase
GB201604633D0 (en) Combination of control interfaces for multiple communicating domains